

Francesco Passamonti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1470175/publications.pdf>

Version: 2024-02-01

306
papers

28,255
citations

8732

75
h-index

5806

161
g-index

315
all docs

315
docs citations

315
times ranked

12433
citing authors

#	ARTICLE	IF	CITATIONS
1	A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. <i>New England Journal of Medicine</i> , 2005, 352, 1779-1790.	13.9	3,240
2	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009, 113, 2895-2901.	0.6	1,110
3	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 392-397.	0.8	854
4	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
5	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , 2010, 115, 1703-1708.	0.6	805
6	Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2005, 23, 7594-7603.	0.8	804
7	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
8	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	13.9	720
9	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. <i>Leukemia</i> , 2013, 27, 1874-1881.	3.3	540
10	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. <i>Leukemia</i> , 2014, 28, 1472-1477.	3.3	465
11	Development and validation of an International Prognostic Score of thrombosis in World Health Organization "essential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012, 120, 5128-5133.	0.6	461
12	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. <i>Leukemia</i> , 2008, 22, 437-438.	3.3	443
13	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184.	0.8	441
14	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
15	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. <i>American Journal of Medicine</i> , 2004, 117, 755-761.	0.6	415
16	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
17	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , 2013, 122, 4047-4053.	0.6	383
18	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. <i>Blood</i> , 2011, 117, 5857-5859.	0.6	376

#	ARTICLE	IF	CITATIONS
19	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	0.8	373
20	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	3.4	362
21	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. <i>Journal of Clinical Oncology</i> , 2012, 30, 4098-4103.	0.8	344
22	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. <i>Leukemia</i> , 2010, 24, 1574-1579.	3.3	321
23	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	0.6	286
24	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. <i>Blood</i> , 2011, 118, 401-408.	0.6	280
25	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. <i>Blood</i> , 2008, 111, 1686-1689.	0.6	264
26	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , 2017, 4, e317-e324.	2.2	243
27	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. <i>Leukemia</i> , 2015, 29, 2126-2133.	3.3	242
28	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017, 31, 2726-2731.	3.3	242
29	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. <i>Haematologica</i> , 2008, 93, 1645-1651.	1.7	241
30	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. <i>Blood</i> , 2006, 107, 3676-3682.	0.6	236
31	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. <i>Blood</i> , 2009, 113, 4829-4833.	0.6	229
32	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2009, 27, 754-762.	0.8	225
33	A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201.	0.6	222
34	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. <i>Blood</i> , 2013, 121, 4778-4781.	0.6	219
35	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4563-4569.	0.8	213
36	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e73-e81.	2.2	211

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. <i>Blood</i> , 2012, 120, 1202-1209.	0.6	205
38	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncology</i> , The, 2017, 18, 88-99.	5.1	205
39	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. <i>Blood</i> , 2011, 117, 2813-2816.	0.6	190
40	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
41	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. <i>American Journal of Hematology</i> , 2014, 89, E121-4.	2.0	176
42	Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. <i>Leukemia</i> , 2008, 22, 905-914.	3.3	175
43	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. <i>Blood</i> , 2005, 106, 3374-3376.	0.6	166
44	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. <i>Cancer</i> , 2014, 120, 513-520.	2.0	165
45	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. <i>Blood</i> , 2010, 116, 2857-2858.	0.6	153
46	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. <i>Blood</i> , 2011, 118, 167-176.	0.6	153
47	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015, 125, 3347-3350.	0.6	152
48	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. <i>Blood</i> , 2007, 110, 485-489.	0.6	148
49	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. <i>British Journal of Haematology</i> , 2010, 148, 961-963.	1.2	144
50	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	1.7	140
51	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017, 129, 3227-3236.	0.6	137
52	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. <i>Blood</i> , 2009, 114, 3538-3545.	0.6	135
53	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. <i>Leukemia</i> , 2010, 24, 1290-1298.	3.3	135
54	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. <i>Journal of Clinical Oncology</i> , 2007, 25, 5630-5635.	0.8	130

#	ARTICLE	IF	CITATIONS
55	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	0.8	127
56	Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. <i>Cancer</i> , 2004, 100, 107-115.	2.0	121
57	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. <i>Leukemia</i> , 2011, 25, 218-225.	3.3	117
58	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. <i>Blood</i> , 2014, 124, 3021-3023.	0.6	112
59	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2007, 18, 346-350.	0.6	111
60	A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. <i>Blood</i> , 2008, 111, 3383-3387.	0.6	108
61	Improving Survival Trends in Primary Myelofibrosis: An International Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2981-2987.	0.8	105
62	Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
63	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210.	3.3	101
64	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTAS study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020, 95, 594-603.	2.0	96
65	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. <i>Blood</i> , 2014, 123, 1833-1835.	0.6	95
66	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	2.2	93
67	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
68	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241.	0.6	90
69	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 2131-2136.	1.9	86
70	What are RBC-transfusion-dependence and -independence?. <i>Leukemia Research</i> , 2011, 35, 8-11.	0.4	84
71	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2013, 121, 4388-4395.	0.6	83
72	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. <i>Cancer</i> , 2006, 107, 2206-2211.	2.0	82

#	ARTICLE	IF	CITATIONS
73	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. <i>American Journal of Hematology</i> , 2016, 91, 681-686.	2.0	80
74	Leukemic transformation of polycythemia vera. <i>Cancer</i> , 2005, 104, 1032-1036.	2.0	79
75	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014, 123, 3803-3810.	0.6	79
76	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. <i>Blood</i> , 2014, 124, 2611-2612.	0.6	79
77	Clinical relevance of JAK2 (V617F) mutant allele burden. <i>Haematologica</i> , 2009, 94, 7-10.	1.7	78
78	Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. <i>British Journal of Haematology</i> , 2007, 136, 301-304.	1.2	76
79	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>British Journal of Haematology</i> , 2013, 162, 229-239.	1.2	75
80	Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. <i>Clinical Cancer Research</i> , 2006, 12, 6487-6493.	3.2	74
81	How I treat polycythemia vera. <i>Blood</i> , 2012, 120, 275-284.	0.6	74
82	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	0.6	70
83	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012, 120, 569-571.	0.6	69
84	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). <i>British Journal of Haematology</i> , 2017, 176, 76-85.	1.2	69
85	The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. <i>Leukemia</i> , 2009, 23, 1924-1926.	3.3	68
86	Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. <i>Haematologica</i> , 2003, 88, 13-8.	1.7	68
87	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 367-374.	1.7	67
88	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	5.8	66
89	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. <i>Haematologica</i> , 2011, 96, 454-458.	1.7	65
90	Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 607-611.	1.7	64

#	ARTICLE	IF	CITATIONS
91	Nongastric Marginal Zone B-cell MALT Lymphoma: Prognostic Value of Disease Dissemination. <i>Oncologist</i> , 2006, 11, 285-291.	1.9	63
92	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. <i>British Journal of Haematology</i> , 2008, 140, 162-168.	1.2	60
93	Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. <i>Annals of Oncology</i> , 2009, 20, 129-136.	0.6	60
94	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. <i>Haematologica</i> , 2011, 96, 167-170.	1.7	60
95	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	0.8	56
96	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
97	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. <i>Leukemia</i> , 2017, 31, 896-902.	3.3	54
98	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. <i>Blood</i> , 2019, 134, 557-557.	0.6	54
99	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. <i>Annals of Hematology</i> , 2018, 97, 1591-1600.	0.8	53
100	Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , 2010, 85, 46-50.	2.0	52
101	JAK Inhibitor in CALR-Mutant Myelofibrosis. <i>New England Journal of Medicine</i> , 2014, 370, 1168-1169.	13.9	52
102	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. <i>Blood</i> , 2017, 130, 1768-1771.	0.6	52
103	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. <i>Oncologist</i> , 2019, 24, e720-e729.	1.9	52
104	Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, S240-S243.	0.6	50
105	Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. <i>American Journal of Hematology</i> , 2012, 87, 669-672.	2.0	49
106	Germline RBBP6 mutations in familial myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 362-365.	0.6	49
107	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
108	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene. <i>Journal of Clinical Oncology</i> , 2013, 31, e269-e271.	0.8	47

#	ARTICLE	IF	CITATIONS
109	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. <i>Thrombosis Research</i> , 2014, 134, 41-43.	0.8	47
110	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <i>American Journal of Hematology</i> , 2016, 91, 918-922.	2.0	47
111	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1855-1864.	2.5	47
112	Transfusion dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis – prognostic relevance is independent of IPSS or karyotype. <i>American Journal of Hematology</i> , 2010, 85, 14-17.	2.0	46
113	Subcutaneous lipoma-like B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2010, 21, 1189-1195.	0.6	46
114	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	1.1	46
115	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	1.7	46
116	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
117	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. <i>Lancet Haematology</i> , 2022, 9, e301-e311.	2.2	46
118	Leukemia risk models in primary myelofibrosis: an International Working Group study. <i>Leukemia</i> , 2012, 26, 1439-1441.	3.3	45
119	Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. <i>Oncotarget</i> , 2011, 2, 485-490.	0.8	44
120	Update from the latest WHO classification of MPNs: a user's manual. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 534-542.	0.9	42
121	Driver mutations effect in secondary myelofibrosis: an international multicenter study based on 781 patients. <i>Leukemia</i> , 2017, 31, 970-973.	3.3	41
122	JAK2 (V617F) mutation in healthy individuals. <i>British Journal of Haematology</i> , 2007, 136, 678-679.	1.2	40
123	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1331-1335.	0.6	40
124	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). <i>Leukemia</i> , 2015, 29, 20-26.	3.3	40
125	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. <i>Leukemia</i> , 2017, 31, 882-888.	3.3	40
126	The role of JAK2 inhibitors in MPNs 7 years after approval. <i>Blood</i> , 2018, 131, 2426-2435.	0.6	40

#	ARTICLE	IF	CITATIONS
127	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. <i>European Journal of Haematology</i> , 2015, 94, 31-36.	1.1	39
128	Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2011, 86, 974-979.	2.0	37
129	Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. <i>Blood</i> , 2021, 138, 2093-2105.	0.6	37
130	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. <i>British Journal of Haematology</i> , 2002, 116, 855-861.	1.2	36
131	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2004, 126, 650-656.	1.2	36
132	Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 411-413.	1.9	36
133	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. <i>British Journal of Haematology</i> , 2010, 149, 455-457.	1.2	36
134	Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. <i>Leukemia</i> , 2002, 16, 2078-2083.	3.3	35
135	Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. <i>American Journal of Hematology</i> , 2006, 81, 124-127.	2.0	35
136	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. <i>Blood Advances</i> , 2022, 6, 373-375.	2.5	34
137	Survival in young patients with intermediate-high risk myelofibrosis: Estimates derived from databases for non transplant patients. <i>American Journal of Hematology</i> , 2009, 84, 140-143.	2.0	33
138	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). <i>Blood</i> , 2012, 120, 801-801.	0.6	33
139	Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. <i>Haematologica</i> , 2003, 88, 1123-9.	1.7	33
140	Combination of Rituximab, Cyclophosphamide, and Vincristine Induces Complete Hematologic Remission of Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 4, 250-252.	2.1	32
141	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	2.0	32
142	correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion dependence. <i>British Journal of Haematology</i> , 2010, 150, 719-721.	1.2	31
143	A novel germline <i>JAK2</i> mutation in familial myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 117-118.	2.0	31
144	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31

#	ARTICLE	IF	CITATIONS
145	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. <i>Blood Advances</i> , 2020, 4, 3708-3715.	2.5	31
146	Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. <i>American Journal of Hematology</i> , 2009, 84, 629-630.	2.0	30
147	Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1587-1589.	1.9	30
148	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 42, 286-291.	0.6	30
149	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. <i>European Journal of Haematology</i> , 2010, 85, 405-415.	1.1	30
150	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. <i>Leukemia</i> , 2018, 32, 2077-2081.	3.3	30
151	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
152	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. <i>HemaSphere</i> , 2021, 5, e612.	1.2	29
153	A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. <i>Blood</i> , 2009, 114, 311-311.	0.6	29
154	Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. <i>The Cochrane Library</i> , 2013, , CD006503.	1.5	28
155	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. <i>Leukemia Research</i> , 2014, 38, 155-160.	0.4	28
156	A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 122.	6.9	28
157	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
158	A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 384-387.	1.3	27
159	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. <i>Journal of Internal Medicine</i> , 2009, 265, 266-274.	2.7	26
160	New generation small-molecule inhibitors in myeloproliferative neoplasms. <i>Current Opinion in Hematology</i> , 2012, 19, 117-123.	1.2	25
161	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , 2021, 35, 3455-3465.	3.3	25
162	Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. <i>Annals of Hematology</i> , 2004, 83, 495-7.	0.8	24

#	ARTICLE	IF	CITATIONS
163	Use of the Functional Assessment of Cancer Therapy [®] Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. <i>Clinical Therapeutics</i> , 2014, 36, 560-566.	1.1	24
164	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	24
165	Defining disease modification in myelofibrosis in the era of targeted therapy. <i>Cancer</i> , 2022, 128, 2420-2432.	2.0	24
166	New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. <i>Current Opinion in Hematology</i> , 2016, 23, 137-143.	1.2	23
167	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. <i>Annals of Hematology</i> , 2018, 97, 617-627.	0.8	23
168	Looking for CALR mutations in familial myeloproliferative neoplasms. <i>Leukemia</i> , 2014, 28, 1357-1360.	3.3	22
169	Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). <i>Blood</i> , 2013, 122, 393-393.	0.6	22
170	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. <i>Human Pathology</i> , 2009, 40, 1628-1637.	1.1	21
171	Everolimus in diffuse large B-cell lymphomas. <i>Future Oncology</i> , 2015, 11, 373-383.	1.1	20
172	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021, 5, e562.	1.2	20
173	Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. <i>Leukemia Research</i> , 2006, 30, 277-282.	0.4	19
174	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO [®] criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015, 90, 434-437.	2.0	19
175	Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 173-182.	1.2	19
176	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.4	18
177	Stem cell transplant in MF: it's time to personalize. <i>Blood</i> , 2019, 133, 2118-2120.	0.6	18
178	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. <i>Blood Advances</i> , 2019, 3, 3196-3200.	2.5	18
179	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase ² (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. <i>British Journal of Haematology</i> , 2022, 198, 317-327.	1.2	18
180	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. <i>Lancet Haematology</i> , 2022, 9, e480-e492.	2.2	18

#	ARTICLE	IF	CITATIONS
181	Exaggerated Insect Bite-like Reaction in Patients Affected by Oncohaematological Diseases. <i>Acta Dermato-Venereologica</i> , 2005, 85, 76-77.	0.6	17
182	It is time to change thrombosis risk assessment for PV and ET?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 121-127.	0.7	16
183	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , 2016, 122, 1888-1896.	2.0	16
184	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	1.3	16
185	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. <i>Blood</i> , 2019, 134, 1708-1711.	0.6	16
186	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808.	3.3	16
187	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
188	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Na ⁺ ve or were Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 668-668.	0.6	16
189	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. <i>Haematologica</i> 2012;97(3):360-5 - Comment. <i>Haematologica</i> , 2012, 97, e5-e6.	1.7	15
190	Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2122-2128.	0.6	15
191	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). <i>Blood</i> , 2013, 122, 4070-4070.	0.6	15
192	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	1.7	15
193	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7001-7001.	0.8	14
194	Disease anticipation in familial myeloproliferative neoplasms. <i>Blood</i> , 2008, 112, 2587-2588.	0.6	13
195	Mutational Status of Myeloproliferative Neoplasms. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2010, 20, 61-76.	0.4	13
196	Novel agents in indolent lymphomas. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 133-148.	1.1	13
197	Ruxolitinib and survival improvement in patients with myelofibrosis. <i>Leukemia</i> , 2015, 29, 739-740.	3.3	13
198	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13

#	ARTICLE	IF	CITATIONS
199	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.4	13
200	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	2.8	13
201	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. <i>Oncology</i> , 2005, 68, 146-153.	0.9	12
202	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkinâ€™s lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 897-912.	1.9	12
203	Validation of the â€œfitness criteriaâ€ for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). <i>Journal of Geriatric Oncology</i> , 2021, 12, 550-556.	0.5	12
204	Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman. <i>Leukemia and Lymphoma</i> , 2003, 44, 1483-1488.	0.6	12
205	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.. <i>Blood</i> , 2009, 114, 1904-1904.	0.6	12
206	New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. <i>Expert Review of Hematology</i> , 2016, 9, 767-780.	1.0	11
207	Directâ€acting antivirals during or after immunochemotherapy in hepatitis C virusâ€positive diffuse large Bâ€cell lymphomas. <i>Hepatology</i> , 2017, 66, 1341-1343.	3.6	11
208	Developments in diagnosis and treatment of essential thrombocythemia. <i>Expert Review of Hematology</i> , 2019, 12, 159-171.	1.0	11
209	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, 0.8 expandedâ€access study. <i>Hematological Oncology</i> , 2021, 39, 558-566.	0.8	11
210	Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	11
211	Deferasirox in the management of ironâ€overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (<scp>IRON</scp>â€EM study). <i>British Journal of Haematology</i> , 2019, 186, e123-e126.	1.2	10
212	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. <i>Blood Advances</i> , 2022, 6, 1162-1174.	2.5	10
213	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. <i>Bone Marrow Transplantation</i> , 2010, 45, 798-800.	1.3	9
214	Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S25-S27.	0.2	9
215	How to manage polycythemia vera. <i>Leukemia</i> , 2012, 26, 870-874.	3.3	9
216	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	1.7	9

#	ARTICLE	IF	CITATIONS
217	Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman. <i>Leukemia and Lymphoma</i> , 2003, 44, 1483-1488.	0.6	8
218	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. <i>Leukemia</i> , 2005, 19, 888-889.	3.3	8
219	Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. <i>Clinical Cancer Research</i> , 2007, 13, 182-186.	3.2	8
220	Blast phase of essential thrombocythemia: A single center study. <i>American Journal of Hematology</i> , 2009, 84, 641-644.	2.0	8
221	Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. <i>International Journal of Cancer</i> , 2009, 124, 2246-2249.	2.3	8
222	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e324-e335.	1.8	8
223	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
224	Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders. <i>Clinical Hematology International</i> , 2021, 3, 77.	0.7	8
225	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 1452-1462.	2.5	8
226	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. <i>Cancers</i> , 2021, 13, 4750.	1.7	8
227	Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy. <i>Blood</i> , 2011, 118, 793-793.	0.6	8
228	High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.. <i>Blood</i> , 2007, 110, 2620-2620.	0.6	8
229	The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence. <i>Blood Reviews</i> , 2022, 54, 100914.	2.8	8
230	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
231	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
232	Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
233	Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 1236-1238.	1.7	7
234	A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion. <i>Leukemia and Lymphoma</i> , 2017, 58, 1977-1980.	0.6	7

#	ARTICLE	IF	CITATIONS
235	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. <i>HemaSphere</i> , 2021, 5, e553.	1.2	7
236	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	0.6	7
237	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 435-435.	0.6	7
238	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. <i>Blood</i> , 2011, 118, 277-277.	0.6	7
239	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. <i>Blood</i> , 2010, 116, 5060-5060.	0.6	7
240	Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. <i>Haematologica</i> , 2006, 91, 159.	1.7	7
241	Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 700-707.	0.3	7
242	Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. <i>Future Oncology</i> , 2022, 18, 2217-2231.	1.1	7
243	Role of the molecular staging and response in the management of follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1018-1022.	0.6	6
244	Validation of cytogenetic-based risk stratification in primary myelofibrosis. <i>Blood</i> , 2010, 115, 2719-2720.	0.6	6
245	RBC-transfusion guidelines update. <i>Leukemia Research</i> , 2012, 36, 659-660.	0.4	6
246	Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 367-373.	1.9	6
247	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	3.3	6
248	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. <i>Blood</i> , 2012, 120, 804-804.	0.6	6
249	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013, 122, 4067-4067.	0.6	6
250	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. <i>Antioxidants</i> , 2022, 11, 113.	2.2	6
251	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 805-807.	0.6	5
252	Clinical Predictors of Outcome in MPN. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1101-1116.	0.9	5

#	ARTICLE	IF	CITATIONS
253	Platelet count predicts driver mutationsâ€™™ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. <i>Leukemia</i> , 2021, 35, 1490-1493.	3.3	5
254	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	5
255	Looking for familial nodular lymphocyteâ€™predominant Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 719-720.	2.0	4
256	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e324-e335.	1.8	4
257	Standard care and investigational drugs in the treatment of myelofibrosis. <i>Drugs in Context</i> , 2019, 8, 1-16.	1.0	4
258	New and old prognostic factors in polycythemia vera. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 19-24.	1.2	3
259	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018, 182, 279-284.	1.2	3
260	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242.	2.0	3
261	Directâ€™acting antivirals in hepatitis C virusâ€™positive mantle cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 263-266.	0.8	3
262	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROME1). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198.	0.6	3
263	Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study.. <i>Blood</i> , 2009, 114, 3904-3904.	0.6	3
264	Navitoclax plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7015-7015.	0.8	3
265	Balancing efficacy and safety of JAK inhibitors in myelofibrosis. <i>Leukemia Research</i> , 2014, 38, 290-291.	0.4	2
266	Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy. <i>Journal of the Neurological Sciences</i> , 2014, 344, 234-235.	0.3	2
267	Response to â€™œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€™by Heidel et al.. <i>Leukemia</i> , 2018, 32, 2727-2728.	3.3	2
268	Chronic myeloproliferative neoplasms in the elderly. <i>European Journal of Internal Medicine</i> , 2018, 58, 33-42.	1.0	2
269	A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!. <i>American Journal of Hematology</i> , 2019, 94, 1303-1305.	2.0	2
270	The EHA Research Roadmap: Malignant Myeloid Diseases. <i>HemaSphere</i> , 2021, 5, e635.	1.2	2

#	ARTICLE	IF	CITATIONS
271	Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study. <i>Blood</i> , 2018, 132, 1655-1655.	0.6	2
272	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. <i>Blood</i> , 2019, 134, 704-704.	0.6	2
273	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. <i>Blood</i> , 2019, 134, 4165-4165.	0.6	2
274	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. <i>Blood</i> , 2005, 106, 791-791.	0.6	2
275	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2010, 116, 1973-1973.	0.6	2
276	Classification of Myeloproliferative Neoplasms and Prognostic Factors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 419-424.	1.8	2
277	Therapy of polycythemia vera: is it time to change?. <i>Oncotarget</i> , 2017, 8, 102759-102760.	0.8	2
278	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2012, 87, 129-130.	2.0	1
279	PDGFRB disease: right diagnosis to prolong survival. <i>Blood</i> , 2014, 123, 3526-3528.	0.6	1
280	Analysis of three screening methods for the detection of calreticulin gene mutations. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e76-e79.	0.7	1
281	Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 987-989.	0.6	1
282	Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072199648.	1.1	1
283	The double significance of idelalisib immune-related toxicity. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-3.	0.6	1
284	Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review. <i>Blood</i> , 2020, 136, 23-23.	0.6	1
285	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. <i>Blood</i> , 2007, 110, 263-263.	0.6	1
286	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. <i>Blood</i> , 2008, 112, 1775-1775.	0.6	1
287	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 2207-2207.	0.6	1
288	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4179-4179.	0.6	1

#	ARTICLE	IF	CITATIONS
289	COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A) Tj ETQq1 1 0.784314rgBT /Over	0.7	0
290	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 1100-1104.	0.8	1
291	Management of Post ET/PV MF: Different from Primary MF. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S24-S26.	0.2	0
292	Understanding New WHO Classification of MPNs. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S91-S92.	0.2	0
293	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. Bone Marrow Transplantation, 2020, 55, 2350-2353.	1.3	0
294	Polycythemia Vera: Is It Time to Rethink Treatment?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S121-S124.	0.2	0
295	Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.. Blood, 2009, 114, 1909-1909.	0.6	0
296	INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia.. Blood, 2009, 114, 2905-2905.	0.6	0
297	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. Blood, 2009, 114, 760-760.	0.6	0
298	Interim 18f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis. Blood, 2011, 118, 5183-5183.	0.6	0
299	Risk Stratification in PMF. , 2012, , 163-175.		0
300	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	0.6	0
301	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	0.6	0
302	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0
303	Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases. Blood, 2021, 138, 1434-1434.	0.6	0
304	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. Blood, 2020, 136, 30-31.	0.6	0
305	A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients. Blood, 2020, 136, 23-24.	0.6	0
306	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. Hematological Oncology, 2022, 40, 1105-1108.	0.8	0